Does exogenous female sex hormone administration affect the rate of tooth movement and root resorption? A systematic review of animal studies

Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis, Athanasios E. Athanasiou

Abstract

Background
The long-term use of contraceptive methods that contain estrogens, progestogens or combinations of the above among women aged 15 to 49 years is extensive. Both estrogens and progestogens affect bone metabolism.

Objective
To systematically investigate and appraise the quality of the available evidence from animal studies regarding the impact of exogenous administration of female sex hormones on the rate of orthodontic tooth movement and root resorption.

Search methods
Search without restriction in seven databases (including grey literature) and hand searching were performed until May 2021.

Selection criteria
We looked for controlled animal studies investigating the effect from exogenous administration of formulations containing female sex hormones on the rate of orthodontic tooth movement and root resorption.

Data collection and analysis
After study retrieval and selection, relevant data was extracted, and the risk of bias was assessed using the SYRCLE’s Risk of Bias Tool. The quality of available evidence was assessed with the Grades of Recommendation, Assessment, Development, and Evaluation.
Results
Three studies were identified, all being at unclear risk of bias. Overall, administration of progestosterone and the combinations of estradiol with norgestrel and desogestrel were shown to significantly decrease the rate of orthodontic tooth movement when given for longer periods (>3 weeks). Inconsistent information was detected for shorter periods of consumption. Estradiol, with desogestrel use, resulted in less root resorption. The quality of the available evidence was considered to be low.

Conclusions
Exogenous administration of female sex hormones may decelerate in the long term the rate of tooth movement and decrease orthodontically induced root resorption in animals. Until more information becomes available, an orthodontist should be able to identify a patient consuming such substances and understand the potential clinical implications and adverse effects that may arise.

Registration
PROSPERO: CRD42017078208; https://clinicaltrials.gov/

Introduction
In many parts of the world, a significant percentage of women have, during their lifetime, used contraception for long periods of time [1,2]. In the United States, more than 25% of women aged 15 to 49 years old are currently using oral contraceptive pills, long-acting reversible contraceptives, or other methods of contraception that contain various estrogens, progestogens or combinations [3]. Both estrogens and progestogens have been shown to affect bone turnover [4].

Exogenous estrogens and progestogens are not only used for hormonal birth control, but also as menopausal hormone therapy. Treatment with estrogens alone in hysterectomized women or in combination with a progestogen in non-hysterectomized women is indicated for the prevention of postmenopausal osteoporosis, as well as the treatment of menopausal symptoms [5]. Estrogens’ administration is indicated in cases of vasomotor symptoms [6] and related genitourinary symptoms of menopause [7]. Estrogens and progestogens can also be used in the treatment of gynecological conditions, like endometrial hyperplasia [8], uterine bleeding [9] and premenstrual syndrome [10], to address infertility [11], as well as to support pregnancy by preventing miscarriage and preterm delivery [12,13].

In the field of orthodontics, thorough documentation of medical history, along with clinical examination and diagnostic records, are always imperative [14]. Specific information on any medication administered is not only significant in recording information about a patient’s health status but might also provide further insights on clinical treatment as well. Medication administration may have varying effects on the rate of orthodontic tooth movement, during active treatment or the post-treatment period, as well as the associated root resorption development [15–20]. Thus, clinicians must be capable of identifying their patients’ medication consumption patterns and understand the potential implications for their treatment.

Information relevant to the impact of exogenous administration of female sex hormones on the rate of orthodontic tooth movement and root resorption should ideally be retrieved from
clinical trials. However, due to ethical reasons and difficulties in recruiting an adequate sample, there is a lack of human studies on this topic. As an alternative, animal experiments are expected to include pertinent information, while circumventing the ethical and practical considerations associated with experimentations on human subjects [21]. Murine reproductive research models have been used extensively for this reason [22]. This is because the estrus cycle of rats is analogous to the human menstrual cycle, not only in terms of the maintenance mechanism, but also regarding hormonal control [23].

**Objective**

The aim of this systematic review was to systematically investigate and assess the quality of the existing available scientific information regarding the rate of tooth movement and orthodontically induced root resorption following the systemic administration of exogenous female sex hormones.

**Materials and methods**

**Protocol and registration**

The present review was based on a protocol developed, registered, carried out and reported following relevant methodological guidelines (PROSPERO: CRD42017078208) (S1 Checklist) [24–27]. As the present study is a systematic review, ethical approval was not necessary.

**Eligibility criteria**

The Participant, Intervention, Comparator, Outcomes and Study design domains were used to describe the eligibility criteria (Table 1). We looked for prospective experimental controlled studies on healthy female animal subjects, assessing the rate of tooth movement and/or root resorption following the administration of exogenous female sex hormones. All types of orthodontic interventions to induce movement of teeth were considered, and the studies had to report on the amount of tooth movement either during the application of orthodontic forces or after their cessation. Tooth movement could be measured in various ways (with calipers, feeler gauges, etc. directly or from plaster models; from histological cuts directly on the optical microscope or from digital photos; radiographs of any kind i.e., lateral cephalometric radiographs, Cone Beam CT, micro-CT, etc.). The amount and extent of root resorption could be investigated histomorphometrically, by scanning electron or 3D surface microscopy or radiographically. Studies on male animals, as well as female animals under medication, with dietary deficiencies, co-morbidities or ovariectomy were excluded. Studies involving animals with additional clinical interventions such as tooth extraction, etc. were also eliminated, as well as studies presenting qualitative assessments. In terms of study design, we planned to select only experimental controlled animal studies and to exclude human, in vitro, ex-vivo or in silico studies; non-comparative studies, reviews, systematic reviews, meta-analyses and studies with fewer than 5 subjects per group analyzed, as per relevant methodological guidelines regarding the consideration of degrees of freedom for treatment comparisons [28,29].

**Information sources and search strategy**

The total content, in 7 databases, (Medline [PubMed], CENTRAL [Cochrane Library; includes records from Embase, CINAHL, ClinicalTrials.gov, WHO’s ICTRP, KoreaMed, Cochrane Review Groups’ Specialized Registers, and records identified by handsearching], Cochrane Database of Systematic Reviews [Cochrane Library], Scopus, Web of Knowledge [including Web of Science Core Collection, KCI Korean Journal Database, Russian Science Citation...
Table 1. Eligibility criteria.

| Domain          | Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-----------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Participants    | • Animal subjects undergoing any kind of active orthodontic tooth movement or after the cessation of orthodontic forces. | • Interventions involving additional interventions, e.g., tooth extraction. • Subjects who present co-morbidities, e.g., osteoporosis. |
| Interventions   | • Systemic administration of female hormones (i.e., per os, intravenously, intraperitoneally, etc.). | • Non-systemic administration. • Administration of substances that are experimental or not prescribed to humans. Simultaneous administration of substances not considered in the present review. • Studies where the active substance or another intervention induced a pathological condition, studies with comorbidities or other conditions. |
| Comparisons     | • Placebo intervention or no intervention.                                          |                                                                                     |
| Outcomes        | • Quantitative data regarding the rate of tooth movement [i.e., the amount of tooth movement in a specific period of time] measured by various ways [callipers, feeler gauges, lateral cephalometric radiographs, Cone Beam CT, etc.]. • Quantitative data regarding the amount and extent of root resorption [number of lacunae, area of lacunae, percentage of resorptive sites compared to the total root area, depth of lacunae, volume of lacunae, etc.] measured by various ways [histomorphometrically, by scanning electron or 3D surface microscopy, radiographically, etc.]. | • Qualitative assessments regarding the rate of tooth movement. • Qualitative assessments regarding the amount and extent of root resorption associated with orthodontic tooth movement. • Inadequate definition of outcomes. |
| Study design    | • Experimental prospective controlled studies (according to the Scottish Intercollegiate Guidelines Network algorithm for classifying study design [available at http://www.sign.ac.uk/assets/study_design.pdf]). | • Non-comparative studies. In vitro or ex-vivo studies. Reviews, systematic reviews and meta-analyses. • Less than 5 subjects per group analyzed. |

https://doi.org/10.1371/journal.pone.0257778.t001

Table 2. Strategy for database search [May 22nd, 2021].

| Database                                      | Search strategy                                                                                          | Hits  |
|-----------------------------------------------|----------------------------------------------------------------------------------------------------------|-------|
| PubMed                                        | (orthodont* [tiab] OR "orthodontic force"[tiab] OR "mechanical force"[tiab]) AND ("tooth movement"[tiab] OR "orthodontic movement"[tiab] OR "orthodontic anchorage"[tiab] OR "root resorption"[tiab])                                      | 4574  |
| Cochrane Central Register of Controlled Trials | (orthodont* OR "orthodontic force" OR "mechanical force") AND ("tooth movement" OR "orthodontic movement" OR "orthodontic anchorage" OR "root resorption") in Record Title OR (orthodont* OR "orthodontic force" OR "mechanical force") AND ("tooth movement" OR "orthodontic movement" OR "orthodontic anchorage" OR "root resorption") in Abstract—(Word variations have been searched) | 2103  |
| Cochrane Database of Systematic Reviews        | (orthodont* OR "orthodontic force" OR "mechanical force") AND ("tooth movement" OR "orthodontic movement" OR "orthodontic anchorage" OR "root resorption") in Record Title OR (orthodont* OR "orthodontic force" OR "mechanical force") AND ("tooth movement" OR "orthodontic movement" OR "orthodontic anchorage" OR "root resorption") in Abstract—(Word variations have been searched) | 20    |
| Scopus                                        | TITLE-ABS ((orthodont* OR "orthodontic force" OR "mechanical force") AND ("tooth movement" OR "orthodontic movement" OR "orthodontic anchorage" OR "root resorption")) AND LIMIT-TO (SUBJAREA,"DENT") AND LIMIT-TO (EXACTKEYWORD,"Tooth Movement")                                           | 1343  |
| Web of Science                               | TITLE: ((orthodon* OR orthodontic force OR mechanical force) AND ("tooth movement" OR orthodontic movement OR orthodontic anchorage OR root resorption)) Timespan: All years. Search language = Auto                                                                 | 1794  |
| Arab World Research Source                   | TI tooth movement OR AB tooth movement                                                                 | 4     |
| ProQuest Dissertations and Theses Global     | ti(orthodont* AND "tooth movement") AND ab(orthodont* AND "tooth movement") [Full text]                                                                 | 141   |

https://doi.org/10.1371/journal.pone.0257778.t002
made by reviewing the reference lists in reviews, included and excluded studies, as well as other related articles. Duplicates were removed using EndNote's duplicate identification strategy (EndNote X9™, Clarivate™, Philadelphia, PA, USA) and then manually by EGK. The corresponding authors of potentially included records were to be contacted, if needed, in order to provide additional data.

Selection process
The titles and abstracts of the retrieved records, followed by the full report of any record considered to meet the inclusion criteria, were assessed independently and in duplicate by EGK and MAM, who were both not blinded. If the abstract was unclear, the full paper was accessed to determine eligibility for inclusion.

Data collection and data items
Special data collection forms were used for data extraction, which was performed independently by the first two authors. The following information was recorded: bibliographic details; information on experimental design and verification of study eligibility; characteristics of the animals (number of animals in each group and sample size calculation; age and weight of animals) and tooth movement mechanics; data on medicinal administration; measurement of outcomes details (orthodontic tooth movement and/or root resorption) and reliability assessment; results. Results were to be extracted and categorized separately for each species or type of mechanics used, since differences are to be expected [30]. Results were also categorized depending on the time period of force application: less than 3 weeks, and 3 weeks or more. Orthodontic tooth movement has been shown to be divided into two phases, a non-linear phase (<3 weeks) and a linear phase thereafter, with the speed of movement peaking at 3 weeks following force application [30,31].

Study risk of bias assessment
The risk of bias in individual studies was assessed with the SYRCLE’s risk of bias tool for animal studies [32] and the summary risk of bias within a study, according to Higgins and co-workers [26]. Assessments were subsequently entered into the Risk-of-bias VISualization (robvis) web application [33]. In all the aforementioned processes, disagreements were settled by discussion with AEA; following the relevant suggestions, kappa statistics were not calculated [26].

Effect measures, synthesis methods, certainty assessment and additional analyses
Although a synthesis of the results was planned, it was ultimately not carried out due to methodological diversity [26]. Due to inadequate information, analyses for “small-study effects” and publication bias, as well as subgroup analyses, were not performed [26]. Finally, despite the lack of extensive information, the quality of available evidence regarding the effect of exogenous female hormone administration on the rate of tooth movement and root resorption after 3 weeks of force application was assessed with the Grades of Recommendation, Assessment, Development, and Evaluation in order to adopt a structured and transparent approach in formulating an interpretation of the evidence [34].
Results

Study selection

The flow of records through the reviewing process is shown in Fig 1. We initially identified 9980 references. We excluded 2856 as duplicates and another 7105 on the basis of their title and abstract. From the nineteen records that remained and were assessed for eligibility, sixteen records were excluded for the following reasons: papers investigating the effect of ovariectomy (5); papers investigating the phases of the menstrual/estrus cycle (5); studies where only the abstract was available (2); papers that constituted hypotheses only (2); a paper that was a review (1); a study that involved other substances (1) (Table 3). Finally, 3 study records were assessed to be eligible for inclusion [35–37].

Study characteristics

The characteristics of the included studies are presented in Table 4. Two of the included studies experimented on rats [36,37], while the third study used rabbits [35]. The duration of force application varied from 2 to 60 days, and female sex hormones were administered for 9 weeks at maximum. In one study, the administration of hormones started one week before the initiation of tooth movement [36], and 6 weeks earlier in another [35]. Orthodontic movement was induced either by reciprocal stainless-steel springs on the incisors [35,36] or by closed coil NiTi spring between incisors and the first molar [37]. The forces exerted ranged between 30-50g.
The retrieved papers investigated the administration of progesterone [35] and the combinations of estradiol with the progestogens norgestrel [36] and desogestrel [37]. All studies reported the rate of tooth movement during the application of orthodontic forces, and only one assessed orthodontically induced root resorption [37]. The rate of tooth movement was measured clinically with calipers, and root resorption was assessed from histological cuts with light microscopy. No sample size calculations were performed, and only Yu et al. assessed the error of the method [37]. No study assessed tooth movement after the cessation of orthodontic forces.

**Risk of bias within studies**

All three studies were assessed to show an unclear risk of bias (Fig 2). All studies were considered to present low risk of bias regarding the items of group similarity and selective reporting.
as well as unclear risk for random sequence generation, allocation concealment, random housing of the animals and blinding of caregivers and investigators. Random selection of animals for outcome assessment was assessed at low risk only for Olyaee et al. [36]. Assessor blinding

### Table 4. Characteristics of the studies included in the systematic review.

| Active substance & study | Subjects & tooth movement model [species; gender; age; weight] | Group characteristics[^§] [no; substance; dosage; route; administration] | Outcomes and methodology | Results[^\*] |
|-------------------------|---------------------------------------------------------------|---------------------------------------------------------------------|------------------------|-----------------|
| Progesterone            | Poosti et al. [2009] [35] | Albino rabbits; female; 2m; 1850g Reciprocal SS springs on CIs [50g] | EG\(_1\): 6; progesterone [5000μg]; IM; every day for 3w EG\(_2\): 5; progesterone [5000μg]; IM; every day for 9w CG: 8 | OTM: Caliper; distance between the mesial corners of Mx Is | EG\(_1\): 1, 2w; ND EG\(_2\): 1, 2w; ND |
|                         |                   | Force application: 3w (1 activation) | Sample size calculation: No | EG\(_1\): 3w; ND EG\(_2\): in EG |
|                         |                   | | Medication administration: 3w [short term]/9w [long term] | |
|                         |                   | | Outcome: OTM < 3w OTM > 3w | |
|                         |                   | | Progestrone | |
| Estradiol + Norgestrel  | Olyaee et al. [2013] [36] | Wistar rats; female; 3m; 250 ±25g Reciprocal SS springs on CIs [30g] | EG: 24; ethinyl estradiol [25μg] + norgestrel [250 μg]; PO; 5d/w PG: 24; saline; PO; daily | OTM: Caliper; distance between the mesial corners of Mx Is | 2d, 1w; ND 2w; ND in EG |
|                         |                   | Force application: 2w (1 activation) | Sample size calculation: No | |
|                         |                   | | Medication administration: 1 before OTM + for 2w after | |
|                         |                   | | Outcome: OTM < 3w OTM > 3w | |
| Estradiol + Desogestrel | Yu et al. [2019] [37] | Sprague-Dawley rats; female; 3m; 250 ±30g NiTi coil springs from Mx FM to CIs [50g] | EG: 40; ethinyl estradiol [18μg] + desogestrel [90μg]; PO daily PG: 40; saline; PO; daily | OTM: Caliper; distance [central fossae of the Mx FM to SM] | 1, 2w; ND in EG 3, 4w; ND in EG |
|                         |                   | Force application: 4w | Sample size calculation: No | |
|                         |                   | | Medication administration: 4w | |
|                         |                   | | Outcome: OTM < 3w OTM > 3w | |
|                         |                   | | Estradiol + | |

[^§]: Dosages were standardized to μg.

[^\*]: All results shown represent comparisons with placebo (preferably) or no pharmacological intervention control groups after specific periods of orthodontic tooth movement.

Box: Central incisor; CG: Control group receiving no kind of pharmacological intervention, neither the vehicle plus the active substance nor the vehicle only; D: Days; EG: Experimental group that received pharmacological intervention, different than placebo; FM: First molar(s); H&E: Hematoxylin and eosin; I: Incisor(s); IM: Intramuscular injection; Mx: Maxillary; m: Month; nd: No difference; OTM: Orthodontic tooth movement; PG: Placebo group receiving the vehicle preparation without the active substance; PO: Per os; RR: Root resorption; SM: Second molar(s); SS: Stainless steel.

https://doi.org/10.1371/journal.pone.0257778.t004

---

#### Fig 2. Risk of bias assessment.

https://doi.org/10.1371/journal.pone.0257778.g002
Effects of exogenous administration of female sex hormones

For the first two weeks after the application of orthodontic forces, progesterone administration in rabbits did not result in any statistically significant difference between the experimental and control group, even for the animals that started the treatment 6 weeks before the placement of the orthodontic appliance. In studies involving rats, the combination of estradiol with desogestrel produced a reduction in tooth movement after 2 weeks, whereas the combination with norgestrel resulted in significant differences in the measurements conducted in both the first and second weeks (Table 4).

Regarding the measurements after the third week of force application, Poosti et al. [35] demonstrated that progesterone resulted in significant decreases in the amount of tooth movement in rabbits, but only in the group that had been exposed to the exogenous hormone for 6 weeks before the initiation of movement. The combination of estradiol with desogestrel also led to a reduction in tooth movement measured in the rats 3 and 4 weeks after the commencement of the experiment [37] (Table 4).

The only study that included assessments of root resorption experimented on rats, and observed reductions in all measurements from the first until the fourth week of force application (Table 4).

Regarding the effect of exogenous female hormone administration on the rate of orthodontic tooth movement and orthodontically induced root resorption, the quality of available evidence was considered as low (Table 5).

### Discussion

The long-term consumption of contraceptives that contain estrogens, progestogens or combinations of them among women aged 15 to 49 years is extensive [1–3]. Both estrogens and progestogens affect bone metabolism [4]. Overall, the hormonal formulations investigated resulted in reductions in the amount of tooth movement when administered for longer periods (>3 weeks). The same was noted for orthodontically induced root resorption. Although the quality of evidence assessment provides insight on the strength of the relevant recommendations, and the information provided is not fully translatable to human clinical scenarios, until more research information becomes available, it could be good practice to identify orthodontic

---

Table 5. Quality of available evidence.

| Studies | Risk of bias | Inconsistency | Indirectness | Imprecision | Other | Effect | Quality |
|---------|--------------|---------------|--------------|-------------|-------|--------|---------|
| Progestrone [rate of tooth movement at 3 weeks] | 1 Serious¹ | Not serious |
| | 2 Serious² | Not serious² |
| | 3 Serious³ | None |
| | | Decrease in the EG | ☯☯ ☯ ☯ LOW |
| Estradiol + Desogestrel [rate of tooth movement at 3 weeks] | 1 Serious¹ | Not serious |
| | 2 Serious² | Not serious² |
| | 3 Serious³ | None |
| | | Decrease in the EG | ☯☯ ☯ ☯ LOW |
| Estradiol + Desogestrel [root resorption at 3 weeks] | 1 Serious¹ | Not serious |
| | 2 Serious² | Not serious² |
| | 3 Serious³ | None |
| | | Decrease in the EG | ☯☯ ☯ ☯ LOW |

EG: Experimental group.

¹Results were based on studies at unclear risk of bias

²Although results cannot be directly extrapolated to human clinical settings they are relevant to the animal setting

³The number of animals analysed was limited.

https://doi.org/10.1371/journal.pone.0257778.t005

was appraised to be at low risk for Poosti et al. [35] and Yu et al. [37], while the handling of incomplete data was at low risk only for Olyaee et al. [36].
patients’ consumption of similar medications and to keep in mind the potential clinical ramifications of such.

Oral contraceptive pills and long-acting reversible contraceptives include two main categories—progestin-only pills, and combinations of estrogens and progestogens [38]. Progestin-only pills function primarily through thickening the cervical mucus, and, secondarily, through inhibiting ovulation to variable degrees, reducing cilia activity in the fallopian tubes, and altering the endometrium [39]. Contraceptives containing both estrogens and progestogens function primarily through inhibition of ovulation via feedback mechanisms in the hypothalamic-pituitary-ovarian axis and thickening of the cervical mucus [38]. The papers used in the present review investigated the effect of progesterone [35] as well as combinations of estrogen with progestogens [36,37], and their results suggested reductions in the speed of orthodontically induced movement and root resorption when administered for longer periods.

Estrogen serum levels are of ovarian origin, and not only regulate female reproductive and sexual function [40], but are also indispensable in maintaining adequate bone mass and mineralization [41,42] through receptors detected in human cells [43]. Especially during pregnancy, estrogens have been found to exert a significant role regarding bone mass preservation [42]. Prevention of bone remodeling by estrogens is a result of osteoclastogenesis prevention from marrow precursors, as well as of inhibition of the Fas/FasL system that enhances osteoclast apoptosis [44,45]. Estrogens lead to a further inhibition in bone resorption through effects on the receptor activator of nuclear factor-Kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system and the production of some pro-resorptive cytokines (e.g., IL-1, IL-6, IL-7, TNF) [46–52]. Moreover, estrogens directly affect osteoblastic cells contributing to bone preservation [53,54].

Progesterone is a steroid sex hormone produced in the ovaries and involved in the menstrual cycle, pregnancy and embryogenesis. It has been shown to possess bone protective qualities [55], directly regulated by progesterone receptors in osteoblasts [56]. These are found in both osteoblasts and osteoclasts [57–59] and are upregulated by estrogen levels, possibly alluding to the fact that the bone effects of estrogens are being partially regulated via progestogens [43,57,58]. In addition, progesterone may participate in the control of bone matrix, through its inhibitory action on metalloproteinases [60,61]. Serum osteocalcin is significantly correlated with progesterone levels, indicating a further interdependence with bone-forming activities [62].

The combinations of estrogens with progestogens for hormonal contraception are extensively researched medications, as they were originally designed for long-term use by young, healthy women, unlike other drugs that are intended for therapeutic effect [63]. Regarding bone mineral metabolism, the effects of these formulations seem to differ between adolescent and adult women. In younger individuals, although this claim is contested, a small overall negative effect seems probable if their use commences very early after menarche. On the contrary, combined oral contraceptives seem to exert a positive effect on bone turnover in adult females [63]. Overall, there seems to be no association between the risk of fractures in the period before menopause and oral contraceptives use [64].

Results from studies on ovariectomized animals provide data that corroborate further the information located in the included studies. After surgical removal of the ovaries, there is a lack of endogenous progesterone and estrogens, resulting in bone loss that initiates in two weeks post-surgery at the earliest, reaches 50% approximately after 4 to 8 weeks, and becomes stable within 12 weeks [65]. Ovariectomy results in osteopenia and osteoporosis and, subsequently, a higher rate of tooth movement [66], while estrogen administration reduces the speed of movement in osteoporotic rats [67,68], as it is closely related to the activity of
osteoclasts [69]. The absence of estrogens has been associated with greater root resorption following orthodontic tooth movement as well [68].

Although the information located from these animal studies was not extensive, some points might be relevant to the treatment of adolescent and adult females using contraceptive methods that involve exogenous hormone administration. An eventual protective effect against root resorption could be important. Given the potentially decelerating effect on tooth movement, an orthodontist should always consider the impact on space closure, frequency of the appointments, and estimation of the duration of orthodontic treatment. Both active and anchor segments’ resistance to movement might be increased, making space closure more challenging, and requiring altered biomechanical systems because of the altered bone turnover [70]. Furthermore, in some stages of treatment, there could be no issue in seeing patients at longer time intervals. Finally, it could be possible that the overall treatment duration might be increased in such circumstances. Although no direct information came out of the material studied, it could be possible that the retention period could be more uneventful in individuals receiving female sex hormones exogenously. Following the removal of orthodontic appliances, the mechanical equilibrium changes immediately, and leads to events analogous to those seen during active treatment, acting in opposite directions [71]. Possible implications could be magnified given the frequently long periods of consumption of such formulations in real life scenarios.

Strengths and limitations

The employed search strategy was comprehensive, all-inclusive, up to May 2021 and followed established guidelines to reduce bias. Most importantly, as similar investigations might encounter significant practical obstacles in human subjects, the current review summarized the available information from animal models that have been used extensively in female reproduction research [22].

There also some limitations that ought to be further elaborated. The level of available evidence was assessed to be low, because of the peculiarities of the eligible studies, regarding nature, characteristics, and the retrieved data. In addition, we were not able to proceed with meta-analysis or other analyses due to the scarcity of information.

Furthermore, it should be highlighted that the presented information is applicable to animals and can be extrapolated to the clinic environment only indirectly. The administered dosages and durations of the tested formulations differ from those used in humans [72]. Also, the route of administration differs, which might lead to different pharmacokinetics and bioavailability [73]. Since different animal species and strains were used in the reviewed experiments, it is important to expect variability in the content and the properties of the bony tissue [74]. The specific biomechanics used to produce the movement of the teeth in the animal experiments are not comparable directly to those used in humans. In addition, in the clinic a patient’s medical status may affect the homeostasis of the periodontal ligament and the movement of the teeth [75,76]. Finally, the eligible studies did not include power sample calculations, possibly leading to problems regarding the precision of the presented results. Thus, the extent of the effect from exogenous female sex hormones administration on orthodontic tooth movement and root resorption is still unclear in human beings. However, executing such studies in humans could prove to be challenging, both ethically and practically.

Recommendations for future research

Since female sex hormones are used widely nowadays among female adolescents and adults, further research is warranted regarding their effect on the phenomena associated with tooth movement and orthodontically induced root resorption. Future studies should follow relevant
guidelines to improve standardization and control the various sources of bias. Finally, to increase generalizability parameters like dosages, duration, and routes of administration, together with the mechanics of movement should be close, as possible, to daily clinical practice.

Conclusions
Based on the compiled information from animal studies, the exogenous female sex hormone administration might result in reductions in orthodontically induced tooth movement and root resorption when administered for longer periods. Although results that derive from animal studies cannot be directly extrapolated to human clinical scenarios, the clinician needs to be aware of the relevant implications in orthodontic treatment.

Supporting information
S1 Checklist. PRISMA 2020 checklist.
(DOCX)

Author Contributions

Conceptualization: Eleftherios G. Kaklamanos, Athanasios E. Athanasiou.
Data curation: Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis.
Formal analysis: Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis.
Investigation: Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis.
Methodology: Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis, Athanasios E. Athanasiou.
Project administration: Eleftherios G. Kaklamanos.
Resources: Eleftherios G. Kaklamanos.
Supervision: Eleftherios G. Kaklamanos.
Validation: Eleftherios G. Kaklamanos.
Visualization: Eleftherios G. Kaklamanos.
Writing – original draft: Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis.
Writing – review & editing: Eleftherios G. Kaklamanos, Miltiadis A. Makrygiannakis, Athanasios E. Athanasiou.

References
1. Daniels K, Mosher WD, Jones J. Contraceptive methods women have ever used: United States, 1982–2010. National Health Statistics Reports; no 62. Hyattsville, MD: National Center for Health Statistics; 2013.
2. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68. https://doi.org/10.1080/13625180410001715681 PMID: 15449817
3. Daniels K, Abma JC. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief, no 388. Hyattsville, MD: National Center for Health Statistics. 2020.
4. Windahl SH, Lerner UH. Mechanical Load, Sex Hormones, and Bone Modeling. In Krishnan V, Kuijpers-Jagtman AM, Davidovitch Zeditors. Biological mechanisms of tooth movement ( 3rd edition). Willey Blackwell, Hoboken, NJ; 2021. pp. 100–116.
25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Maltby CD, et al. (2021) Updating guid-
lines for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidem. 2021; 134: 103–112. https://doi.org/10.1016/j.jclinepi.2021.02.003 PMID: 33577987

24. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endome-
trial hyperplasia. J Gynecol Oncol. 2016; 27: e8. https://doi.org/10.3802/jgo.2016.27.e8 PMID:
26463434

23. Motta T, Lagana AS, Valenti G, LA Rosa VL, Noventa M, Vitagliano A, et al. [Differential diagnosis and
management of abnormal uterine bleeding in adolescence]. Minerva Ginecol. 2017; 69: 618–630. 
https://doi.org/10.23736/S0026-4784.17.04090-4 PMID: 29082726

22. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database
Syst Rev. 2012; 14;2012 : CD003415. https://doi.org/10.1002/14651858.CD003415.pub4 PMID:
22419287

21. Kaklamanos EG, Makrygiannakis MA, Athanasiou AE. Could medication s and biologic factors affect
the rate of orthodontic tooth movement? A systematic review. Eur J Orthod. 2018; 40: 649–659. https://doi.
org/10.1093/ejo/cjy048 PMID: 29992228

20. Makrygiannakis MA, Kaklamanos EG, Athanasiou AE. Does common prescription medication affect
the rate of orthodontic tooth movement? A systematic review. Eur J Orthod. 2018; 40: 649–659. https://doi.
org/10.1093/ejo/cjy048 PMID: 29992228

19. Kaklamanos EG, Makrygiannakis MA, Athanasiou AE. Does medication administration affect the rate
of orthodontic tooth movement and root resorption development in humans? A systematic review. Eur J
Orthod. 2020; 42: 407–414. https://doi.org/10.1093/ejo/cjz063 PMID: 31421637

18. Kaklamanos EG, Makrygiannakis MA, Athanasiou AE. Does long-term use of pain relievers have an
impact on the rate of orthodontic tooth movement? A systematic review of animal studies. Eur J Orthod.
2019; 4: 346–359. https://doi.org/10.1093/ejo/cjy079 PMID: 30590549

17. Makrygiannakis MA, Kaklamanos EG, Athanasiou AE. Does common prescription medication affect
the rate of orthodontic tooth movement? A systematic review of animal studies. Eur J Orthod. 2018; 40:
649–659. https://doi.org/10.1093/ejo/cjy048 PMID: 29992228

16. Proffit WR, Fields HW Jr, Larson B, Sarver DM. Contemporary Orthodontics, 6th ed. St Louis, MO:
Mosby Elsevier; 2018.

15. Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, et al. Sporadic
miscarriage: evidence to provide effective care. Lancet. 2021; 397: 1668–1674. https://doi.org/10.1016/
S0140-6736(21)00683-8 PMID: 33915095

14. Makrygiannakis MA, Kaklamanos EG, Athanasiou AE. Does common prescription medication affect
the rate of orthodontic tooth movement? A systematic review of animal studies. Eur J Orthod.
2018; 40: 649–659. https://doi.org/10.1093/ejo/cjy048 PMID: 29992228

13. Mirza FG, Patki A, Pexman-Fieth C. Dydrogestrone use in early pregnancy. Gynecol Endocrinol. 2015; 8:
769–784. https://doi.org/10.1586/17512433.2015.1099432 PMID: 26482902

12. Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, et al. Sporadic
miscarriage: evidence to provide effective care. Lancet. 2021; 397: 1668–1674. https://doi.org/10.1016/
S0140-6736(21)00683-8 PMID: 33915095

11. Shamseer L, Moher D, Clarke M, Gherey D, Liberati A, Petticrew M, et al. Preferred reporting items for
systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ
(Clinical research ed.). 2015; 350: g7647. https://doi.org/10.1136/bmj.g7647 PMID: 25555855

10. Makrygiannakis MA, Kaklamanos EG, Athanasiou AE. Does long-term use of pain relievers have an
impact on the rate of orthodontic tooth movement? A systematic review of animal studies. Eur J Orthod.
2019; 41: 468–477. https://doi.org/10.1093/ejo/cjy079 PMID: 30590549

9. Motta T, Lagana AS, Valenti G, LA Rosa VL, Noventa M, Vitagliano A, et al. [Differential diagnosis and
management of abnormal uterine bleeding in adolescence]. Minerva Ginecol. 2017; 69: 618–630. 
https://doi.org/10.23736/S0026-4784.17.04090-4 PMID: 29082726

8. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endome-
trial hyperplasia. J Gynecol Oncol. 2016; 27: e8. https://doi.org/10.3802/jgo.2016.27.e8 PMID:
26463434

7. Rahn DD, Carberry C, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database
Syst Rev. 2012; 14;2012 : CD003415. https://doi.org/10.1002/14651858.CD003415.pub4 PMID:
22419287

6. Komm BS, Morgenstern D, A Yamamoto L, Jenkins SN. The safety and tolerability profile of therapies
for the prevention and treatment of osteoporosis in postmenopausal women. Expert Rev Clin Pharma-
col. 2015; 8: 769–784. https://doi.org/10.1586/17512433.2015.1099432 PMID: 26482902

5. Burgos N, Cintron D, Latortue-Albino P, Serrano V, Rodriguez Gutierrez R, Faubion S, et al. Estrogen-
based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine.
2017; 58: 413–425. https://doi.org/10.1007/s12020-017-1435-x PMID: 29039146

4. Proffit WR, Fields HW Jr, Larson B, Sarver DM. Contemporary Orthodontics, 6th ed. St Louis, MO:
Mosby Elsevier; 2018.

3. Levine JE (2015) Neuroendocrine Control of the Ovarian Cycle of the Rat. In Plant TM, Zeleznik JA, edi-
tors. Knobil and Neill’s Physiology of Reproduction ( 4th ed.). London, UK: Academic Press; 2015. pp.
1199–1258.

2. Burgos N, Cintron D, Latortue-Albino P, Serrano V, Rodriguez Gutierrez R, Faubion S, et al. Estrogen-
based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine.
2017; 58: 413–425. https://doi.org/10.1007/s12020-017-1435-x PMID: 29039146

1. Komm BS, Morgenstern D, A Yamamoto L, Jenkins SN. The safety and tolerability profile of therapies
for the prevention and treatment of osteoporosis in postmenopausal women. Expert Rev Clin Pharma-
col. 2015; 8: 769–784. https://doi.org/10.1586/17512433.2015.1099432 PMID: 26482902
26. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Ed. London, UK: The Cochrane Collaboration and John Wiley & Sons Ltd; 2019.

27. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. System Rev. 2021; 10: 39.

28. Mead R, Gilmour SG, Mead A. Statistical Principles for the Design of Experiments. Cambridge, UK: Cambridge University Press; 2012.

29. Kirkwood J, Hubrech R. The UFAW Handbook on the Care and Management of Laboratory and Other Research Animals. 8th Edition. Chichester, UK: Wiley-Blackwell; 2010.

30. Ren Y, Maltha JC, Kuipers-Jagtman AM. The rat as a model for orthodontic tooth movement—a critical review and a proposed solution. Eur J Orthod. 2004; 26: 483–490. https://doi.org/10.1093/ejo/26.5.483 PMID: 15536836

31. Ren Y, Maltha JC, Van ’t Hof MA, Kuipers-Jagtman AM. Age effect on orthodontic tooth movement in rats. J Dent Res. 2003; 82: 38–42. https://doi.org/10.1177/154405910308200109 PMID: 12508043

32. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M., Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014; 14: 43. https://doi.org/10.1186/1471-2288-14-43 PMID: 24667063

33. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021; 12: 55–61. https://doi.org/10.1002/jrsm.1411 PMID: 32336025

34. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64: 383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026 PMID: 2195583

35. Poosti M, Basafa M, Eslami N. Progesterone effects on experimental tooth movement in rabbits. J Calif Dent Assoc. 2009; 37: 483–486. PMID: 19653405

36. Olyaee P, Mirzakouchaki B, Ghajar K, Seyyedi SA, Shalchi M, Gharani A, et al. The effect of oral contraceptives on orthodontic tooth movement in rat. Med Oral Patol Oral Cir Bucal. 2013; 18: e146–e150. https://doi.org/10.4317/medoral.18048 PMID: 23229247

37. Yu J, Zhou Y, Zhang T, Lv J, Firth F, Zhao X, et al. Effect of combined oral contraceptives on orthodontic tooth movement in a female rat model. Aust Orthod J 2019; 35: 127–133.

38. Powell A. Choosing the right oral contraceptive pill for teens. Pediatr Clin North Am. 2017; 64: 343–358. https://doi.org/10.1016/j.pcl.2016.11.005 PMID: 28292450

39. Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, editors. Contraceptive Technology: Twentieth Revised Edition. New York: Ardent Media; 2011.

40. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002; 346: 340–52. https://doi.org/10.1056/NEJMra000471 PMID: 11821512

41. Conneely OM. Perspective: female steroid hormone action. Endocrinology. 2001; 142:2194–2199. https://doi.org/10.1210/endo.142.6.8288 PMID: 11356662

42. Windahl SH, Andersson G, Gustafsson JA. Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol Metab. 2002; 13: 195–200. https://doi.org/10.1016/s1043-2760(02)00594-5 PMID: 12185665

43. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988; 241: 84–86. https://doi.org/10.1126/science.3388021 PMID: 3388021

44. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130: 811–823. https://doi.org/10.1016/j.cell.2007.07.025 PMID: 17803905

45. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifi R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001; 276: 8836–8840. https://doi.org/10.1074/jbc.M010764200 PMID: 11124127

46. Xu Y, Chu N, Qiu X, Gober HJ, Li D, Wang L. The interconnected role of chemokines and estrogen in bone metabolism. Biosci Trends. 2017; 10: 433–444. https://doi.org/10.5582/bst.2016.01072 PMID: 27725618

47. Weitzmann MN, Pacifi R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006; 116: 1186–1194. https://doi.org/10.1172/JCI28850 PMID: 16670759

48. Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of osteoporosis. Clin Ther. 2015; 37: 1837–1850. https://doi.org/10.1016/j.clinthera.2015.06.006 PMID: 26163201
49. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005; 328: 688–696. https://doi.org/10.1016/j.bbrc.2004.11.097 PMID: 15694402

50. Keams AE, Khosla S, Kosteniuk PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008; 29: 155–192. https://doi.org/10.1210/er.2007-0014 PMID: 18057140

51. Turner RT, Colvard DS, Spelsberg TC. Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins. Endocrinology. 1990; 127: 1346–1351. https://doi.org/10.1210/endo-127-3-1346 PMID: 2387257

52. Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol. 2008; 252: 68–80. https://doi.org/10.1016/j.cellimm.2007.06.008 PMID: 17884117

53. Konidoh S, Inoue K, Igarashi K, Sugizaki H, Shirode-Fukuda Y, Inoue E, et al. Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice. Bone. 2014; 60: 68–77. https://doi.org/10.1016/j.bone.2013.12.005 PMID: 24333171

54. Määttä JA, Büki KG, Gu G, Alanne MH, Väänänen J, Liljenbäck H, et al. Inactivation of estrogen receptor α in bone-forming cells induces bone loss in female mice. FASEB J. 2013; 27: 478–488. https://doi.org/10.1001/jk_mr.2013.213587 PMID: 23073829

55. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997; 18: 502–519. https://doi.org/10.1210/edrv.18.4.0308 PMID: 9267762

56. Wei LL, Leach MW, Miner RS, Demers LM. Evidence for progesterone receptors in human osteoblast-like cells. Biochem Biophys Res Commun. 1993; 195: 525–532. https://doi.org/10.1006/bbrc.1993.2077 PMID: 7690554

57. MacNamara P O'Shaughnessy C, Manduca P, Loughrey HC. Progesterone receptors are expressed in human osteoblast-like cells and in primary human osteoblast cultures. Calcif Tissue Int. 1995; 57: 436–441. https://doi.org/10.1007/BF00301947 PMID: 8581876

58. Pensler JM, Langman CB, Radosevich JA, Maminta ML, Mangkornkanok M, et al. Sex steroid hormone receptors in normal and dysplastic bone disorders in children. J Bone Miner Res. 1990; 5: 493–498. https://doi.org/10.1002/jbrm.5650050511 PMID: 2368630

59. Mills EG, Yang L, Nielsen MF, Kassem M, Dhillo WS, Comninos AN. The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens. Endocrine Rev. 2021 [epub]. https://doi.org/10.101210/edrv/bnab015 PMID: 33901271

60. Singh AK, Chattopadhay ray R, Chakravarty B, Chaudhury K. Altered circulating levels of matrix metalloproteinases 2 and 9 and their inhibitors and effect of progesterone supplementation in women with endometriosis undergoing in vitro fertilization. Fertil Steril. 2013; 100: 127–34.e1. https://doi.org/10.1016/j.fertnstert.2013.03.006 PMID: 23557756

61. Allen TK, Feng L, Grotegut CA, Murtha AP. Progesterone receptor membrane component 1 as the mediator of the inhibitory effect of progestins on cytokine-induced matrix metalloproteinase 9 activity in vitro. Reprod Sci. 2014; 21: 260–268. https://doi.org/10.1177/19337191113493514 PMID: 23813454

62. Haruyama N, Igarashi K, Saeki S, Otsuka-Isoya M, Shinoda H, Mitani H. Estrous-cycle-dependent variation in orthodontic tooth movement. J Dent Res. 2002; 81: 406–410. https://doi.org/10.1016/j.bone.2013.12.005 PMID: 24333171

63. Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev Clin Pharmacol. 2017; 10: 315–326. https://doi.org/10.1080/17512433.2017.1271708 PMID: 27977304

64. Scholes D, LaCroix AZ, Hubbard RA, Ichikawa LE, Spangler L, Opgeskalski BH, et al. Oral contraceptive use and fracture risk around the menopausal transition. Menopause. 2016; 23: 166–74. https://doi.org/10.1097/GME.0000000000000595 PMID: 26757274

65. Wronska TJ, Dann LM, Scott KS, Cintrón M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int. 1989; 45: 360–366. https://doi.org/10.1007/BF02556007 PMID: 2509027

66. Mohammed AO, Kaklamanos EG. Effect of ovariectomy-induced osteoporosis on the amount of orthodontic tooth movement: a systematic review of animal studies. Eur J Orthod. 2021 [epub]. https://doi.org/10.1093/ejor/joab013 PMID: 33866368

67. Jin Z, Ding Y, Li X. Effects of estrogen on experimental tooth movement in osteoporosis rats. Chin J Stomatol. 2000; 35: 55–57. PMID: 11831967

68. Amaro ERS, Ortiz FR, Dorneles LS, Santos MS, Barrioni BR, Miranda RM, et al. Estrogen protects dental roots from orthodontic-induced inflammatory resorption. Arch Oral Biol. 2020; 117: 104820. https://doi.org/10.1016/j.archoralbio.2020.104820 PMID: 32592932

69. Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a bisphosphonate (AEXBuBP) on tooth movements in rats. Am J Orthodont Dentofacial Orthop. 1994; 106: 279–289. https://doi.org/10.1016/S0889-5406(94)70048-6 PMID: 8074093
70. Melsen B. (2012) Potential Adult Orthodontic Patients—Who Are They? In: Melsen B., editor. Adult orthodontics. London, UK: Blackwell Publishing. 2012; pp. 1–11.

71. Maltha JC, Kuipers-Jagtman AM, Von den Hoff JW, Ongkosuwito EM. Relapse revisited—Animal studies and its translational application to the orthodontic office. Semin Orthod. 2017; 23: 390–398.

72. Joint Formulary Committee. (2017) British National Formulary 73. London, UK: BMJ Publishing and the Royal Pharmaceutical Society.

73. Buxton ILO, Benet LZ. Pharmacokinetics: The dynamics of drug absorption, distribution, metabolism and elimination. In Brunton L, editor, Chabner BA, Knollmann BC, associate editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw Hill; 2011, pp. 17–40.

74. Aersens J, Boonen S, Lowet G, Dequeker J. Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research. Endocrinology, 1998; 139: 663–670. https://doi.org/10.1210/endo.139.2.5751 PMID: 9449639

75. Jiang N, Guo W, Chen M, Zheng Y, Zhou J, Kim SG, et al. Periodontal ligament and alveolar bone in health and adaptation: tooth movement. Front Oral Biol. 2016; 18: 1–8. https://doi.org/10.1159/000351894 PMID: 26599112

76. Xiao W, Wang Y, Pacios S, Li S, Graves, DT. Cellular and molecular aspects of bone remodeling. Front Oral Biol. 2016; 18: 9–16. https://doi.org/10.1159/000351895 PMID: 26599113